| cbdMD (NYSE American: YCBD) Appoints Scott Coffman co-CEO and Caryn Dunayer President |
| |
|
cbdMD (NYSE American: YCBD) announced the appointment of co-founders Scott Coffman and Caryn Dunayer co-CEO and President, respectively, effective immediately. Coffman will share CEO duties with Martin A. Sumichrast, who will remain chairman of the board. Sumichrast will continue to focus on shareholder and public company aspects while Coffman will oversee the operational aspects of the company.
Key Quote: “In December of 2018, Scott and Caryn joined our company when we purchased the cbdMD brand. Both Scott and Caryn are extremely versatile and talented brand builders. With the rebranding of our company now complete, I believe their experience and knowledge will be an asset in propelling cbdMD forward as we execute on our mission to become the most trusted CBD brand in America.” – Martin Sumichrast, Chairman & co-CEO
The Backstory: cbdMD is a nationally recognized consumer cannabidiol (CBD) brand whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils, and CBD pet products. cbdMD was founded by Scott Coffman, the founder of well-known e-cigarette brand Blu, which he later sold to Lorillard Tobacco for $135 million. Coffman continues to lead cbdMD, is on the Company’s board, and is one of its largest shareholders. With a strong cash position (completed $13M+ offering in May 2019) and the benefit of the expected increase in major retailer acceptance from the passage of the 2018 Farm Bill, cbdMD believes it can accelerate revenue growth in this rapidly expanding market. The Company has set targets of more than $20 million in revenue for 2019 and more than $300 million in aggregate revenue over the next five years.
Disclosure
cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL) Increases Lithium Resource by 47% to 27.9M Tons |
| |
|
Piedmont Lithium (NASDAQ: PLL) announced a major update to its Mineral Resource estimate for the company’s wholly owned project located within the world-class Carolina Tin-Spodumene Belt (“TSB”) in North Carolina.
Why It Matters: The Mineral Resource for the Core property has increased to 25.1 million tonnes (“Mt”) at a grade of 1.09% Li2O, bringing the Project’s total Mineral Resources to 27.9 Mt at a grade of 1.11% Li2O, containing 309,000 tons of lithium oxide (“Li2O”) or 764,000 tonnes of lithium carbonate equivalent (“LCE”) (the benchmark used in the lithium industry). Importantly, 74% of the Core Mineral Resource is within 100m of surface and 97% is within 150m of surface. Approximately 50%; or 12.5 million tons of the Mineral Resource is classified in the Indicated Resource category. All of the Mineral Resource tons at both Core and Central properties are attributable to spodumene mineralization.
Key Quote: “We are very pleased with the resource update at our Core property, bringing our total project-wide resources to 27.9Mt at 1.11% Li2O. As we expand our land holdings and drill out other highly prospective targets, we are optimistic that we will ultimately identify North America’s largest spodumene ore body. This scale, combined with high grade, strong mineralogy and metallurgy, and our superior location in North Carolina, all support the unique strategic nature of the Piedmont Lithium Project.” – Keith Phillips, President & CEO
What’s Next: The Company expects to complete a pre-feasibility level metallurgical testwork program followed by a Scoping Study update in July 2019.
Disclosure
Piedmont Lithium (NASDAQ: PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| Immuron (NASDAQ: IMRN) Directors Increase Shareholdings in the Company |
| |
|
Immuron Ltd. (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, wishes to advise that two of its Directors, Mr Peter Anastasiou and Mr Daniel Pollock, have recently acquired on-market 1,000,000 (25,000 ADS equivalent) and 145,000 (3,625 ADS equivalent) IMC fully paid ordinary shares (‘acquisitions’) respectively since May 2019.
Key Quote: “We have been committed to Immuron for the long haul and this recent investment demonstrates our confidence that CEO Gary Jacobs has got the strategy right. Travelan, a successful diarrhea preventative, which has been a good product for the Company over the past few years, has now been recognized as potentially a real company maker once through FDA and into US pharmaceutical sales pipelines. We definitely see this as a positive transition stage to growth for Immuron.” — Peter Anastasiou, Immuron Director
The Backstory: Immuron Ltd. is an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron’s technology platform utilizes highly specific vaccines for the generation of hyperimmune antibody-rich bovine colostrum, providing a means of antimicrobial therapy without the drawbacks of antibiotics to treat gut-mediated diseases. The Company currently markets Travelan®, which is a listed medicine on the Australian Register for Therapeutic Goods, in Australia to reduce the risk of travelers’ diarrhea.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| Catasys (NASDAQ: CATS) Announces Addition to Russell 3000® and 2000® Indexes |
| |
|
Catasys (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, announced that it has been added to the Russell 3000® and 2000® Indexes, effective after the U.S. markets open on Monday, July 1, 2019, as part of the 2019 Russell U.S. Indexes reconstitution.
Key Quote: “We are very pleased to have earned our inclusion in the Russell Indexes. Our Company has followed a disciplined strategy that has resulted in steady growth and increased success in identifying, engaging and treating individuals suffering from the consequences of behavioral health disease.” — Terren Peizer, Catasys Chairman and CEO
The Backstory: Catasys harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and validated outcomes and savings to health plans. The mission of the Company is to help improve the health and save the lives of as many people as possible. Catasys's integrated, technology-enabled OnTrak solution—contracted with a growing number of national and regional health plans—is designed to treat members with behavioral conditions that cause or exacerbate co-existing medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure, which result in high medical costs.
Disclosure
Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Closes Second Order of Contract to Supply $109M of Premium Hemp Flower |
| |
|
SinglePoint (OTCQB: SING) announced a $109M+ contract with Elite Foundation of North Carolina to supply more than 275,000 pounds of premium hemp flower over a period of 15 months. The client has approved and taken receipt of the second batch of product and Elite has approved approximately 5000 pounds of varietal strain hemp flower which has been reserved for their next 4 to 6 shipments expected every other week.
Key Quote: “We are grateful for the opportunity to work with SinglePoint in continuing to establish ourselves as the Southeast’s preferred hemp provider, trusted to satisfy our clientele’s growing demands by ensuring quality, consistency and variety for the downline. This alliance potentiates a cascade of mutual benefits across many sectors within the burgeoning hemp industry, and we look very much forward to generating these positive energies together!” – Max Alexander, Chairman and CFO of Elite Foundation
The Backstory: BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024 while New York-based investment bank Cowen & Co, estimates that the market could pull in $15 billion by 2025. The smokable hemp market currently represents approximately 2% of the overall CBD market, but with a 250% growth from 2017 to 2018, Brightfield Group, a Chicago-based cannabis market research firm, identifies dried and smokable hemp flowers as one of the fastest-growing segments of the CBD market. SinglePoint’s bold entry into the hemp flower market positions the company as one of the leading hemp flower wholesalers in the country. With the passage of the 2018 Farm Bill and the mainstreaming of CBD hemp flower, the market is growing rapidly. There is a significant need for reliable suppliers with the capacity to move product. Its demonstrated capacity to deliver has established SinglePoint as one of the dominant players in the hemp flower marketplace.
Disclosure
SinglePoint, Inc. (OTCQB: SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Santa Fe Gold (OTC: SFEG) Ramps Up Development at Historic Jim Crow Gold & Silver Mine |
| |
|
Santa Fe Gold (OTC: SFEG), a U.S. based mining company and owner of 148 mining claims covering 42 mine sites and potential mines, announced it has been steadily increasing production of potentially economic grade, high silica vein material from its Jim Crow mine.
Why It Matters: The Steeple Rock Mining District contains numerous deposits of high Silica content quartz vein rock. Santa Fe Gold has marketed similar material to several copper smelters in the past, where it was used as a fluxing agent in the copper smelting process. Careful sampling and analysis of this vein from the 200-foot depth level development headings leads Santa Fe management to believe that this new zone is of an acceptable quality to be shipped to smelters, after crushing to a 3/8-inch specification. Santa Fe Gold believes that it can develop enough tonnage in this zone to be able to demonstrate the capacity to fulfill a long-term supply contract as required by smelters.
What’s Next: Management’s initial goal is to be able to produce between 50 to 100 tons per day from the Jim Crow Mine. If achieved, further development of the Jim Crow vein both laterally and at depth will be explored. Thereafter, Santa Fe Gold would plan to develop additional mineralized and parallel veins believed to be present up to the surface representing further potential targets to be developed from the existing working levels of the Jim Crow Mine.
Once full production can be achieved from the Jim Crow Mine, the plan is to further exploit and develop the adjacent Imperial Mine. Potential “down dip” extension of the Imperial vein should be able to be accessed from the Jim Crow Mine by extending the 300 level approximately 300 feet to the southeast. We believe that historic diamond drilling indicates mineralized quartz veins are present within the area. Another similar mine, the Billali, is situated some four miles north and SFEG plans to develop this mine in due course.
Disclosure
Santa Fe Gold Corp. (OTC: SFEG) is a client of RedChip Companies, Inc. SFEG agreed to pay RedChip Companies, Inc. 1,000,000 shares of Rule 144 stock for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Medovex Corporation (OTCQB: MDVX) Updates Name Change and Full Rebranding to H-CYTE |
| |
|
Medovex Corp. (OTCQB: MDVX) updated investors on its name change and rebranding to H-CYTE. The announcement underscores the Company's broader commitment to focusing on delivering regenerative anti-inflammatory solutions to treat the unmet needs of patients, as well as bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases.
In addition to the name and anticipated symbol change, the Company will launch a new corporate website and social channels to provide educational resources for patients. The name change and an accompanying ticker symbol remain subject to the approval of the Financial Industry Regulatory Authority (FINRA). Until that date, the Company’s stock will continue to trade under the existing “MDVX” ticker symbol.
Key Quote: “2019 has already been a critical year for our organization. Year to date, we have announced the successful asset purchase of Regenerative Medicine Solutions LLC, established a world-class management team with a documented track record of success, appointed numerous trusted industry veterans to our board of directors, and secured financing to continue to execute our business plan.” — CEO Bill Horne
The Backstory: H-CYTE was formed to build and develop a diversified portfolio of innovative medical technology products and services to improve quality of life for patients. The DenerveX® System is H-CYTE’s first product and is intended to provide long-lasting relief from pain associated with facet joint syndrome. For biomedical services, H-CYTE manages Lung Health Institute. Lung Health Institute is a leader in regenerative medicine that specializes in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases. In late 2019, H-CYTE’s biologics division, LungCYTE, plans to submit an IND to the FDA to study novel and proprietary biologics for treatment of COPD. For more information about H-CYTE, please visit www.Medovex.com.
|
|
| |
|
| |
| Quote of the Week |
| |
"You can’t be right all the time, but you can surround yourself with honest people."
- John Pappajohn, Venture Capitalist |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
If you received this email by mistake you can unsubscribe from all emails.
|
|
|
|
|
